EMA Authorised: Pavblu (aflibercept) — Amgen Technology (Ireland) UC

View source ↗

Summary

EMA has authorised Pavblu (aflibercept) by Amgen Technology (Ireland) UC for multiple ocular indications including wet age-related macular degeneration, diabeti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• PAVBLU (AFLIBERCEPT-AYYH)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Retinal Vein Occlusion;Choroidal Neovascularization;Diabetes Complications. MAH: Amgen Technology (Ireland) UC. Decision date: 14/04/2026